Prognostic Value of Epithelial Growth Factor Receptor, Vascular Endothelial Growth Factor, E-Cadherin, and p120 Catenin in Resected Non-Small Cell Lung Carcinoma;Valor pronóstico del receptor del factor de crecimiento epitelial, factor de crecimiento endotelial vascular, E-cadherina, y p120 catenina en el carcinoma de pulmón no microcítico resecado

Archivos de Bronconeumologia

Volumn 47, Issue 8, 2011, Pages 397-402

  Ucvet, Ahmet ^a   Kul, Cemil ^a   Gursoy, Soner ^a   Erbaycu, Ahmet Emin ^a   Kaya, Seyda Ors ^a   Dinc, Zekiye Aydogdu ^a   Yucel, Nur ^a  

^a Dr Suat Seren Chest Diseases and Thoracic Surgery Training Hospital   (Turkey)

Author keywords

E cadherin; Epithelial growth factor receptor; Lung cancer; Non small cell carcinoma; P120 catenin; Surgery; Vascular endothelial growth factor

Indexed keywords

CATENIN; EPITHELIAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN P120; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; AGED; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG RESECTION; MALE; NON SMALL CELL LUNG CANCER; PROSPECTIVE STUDY; STAINING; TUMOR DIFFERENTIATION;

EID: 85047696248     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.04.005     Document Type: Article

References (30)

1. Tanoue T., Matthay A. Lung cancer: epidemiology and carcinogenesis. General Thoracic Surgery 2000 p, 1215-1228. Lippincott Wiliams & Wilkins, Philadelphia. 5th ed. T.W. Shields, J. LoCicero, R.B. Ponn (Eds.).
2. Fukasawa T., Fujisawa T., Yamaguchi Y., Sasaki K., Shiba M., Yusa T., et al. Clinical evaluation of serum NSE and CEA in primary lung cancer patients. Gan To Kagaku Ryoho 1986, 13:1862-1867.
3. Scagliotti G.V., Selvaggi G., Novello S., Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004, 10:4227-4232.
4. Bencardino K., Manzoni M., Delfanti S., Riccardi A., Danova M., Corazza G.R. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Intern Emerg Med 2007, 2:3-12.
5. Berghmans T., Meert A.P., Martin B., Ninane V., Sculier J.P. Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. Eur Respir J 2005, 25:329-335.
6. Tamura M., Ohta Y., Nakamura H., Oda M., Watanabe G. Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers 2002, 17:275-279.
7. Volm M., Mattern J., Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res 1999, 19:1669-1671.
8. Liao M., Wang H., Lin Z., Feng J., Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001, 33:125-132.
9. Kase S., Sugio K., Yamazaki K., Okamoto T., Yano T., Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000, 6:4789-4796.
10. Bremnes R.M., Veve R., Gabrielson E., Hirsch F.R., Baron A., Bemis L., et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002, 20:2417-2428.
11. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
12. Travis W.D., Brambilla E., Müller-Hermelink H.K., Harris C.C. Tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours 2004, IARC Press, Lyon.
13. D'Amico T.A., Massey M., Herndon J.E., Moore M.B., Harpole D.H. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999, 117:736-743.
14. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005, 23:3235-3242.
15. Rabiasz G.J., Langdon S.P., Bartlett J.M., Crew A.J., Miller E.P., Scott W.N., et al. Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. Br J Cancer 1992, 66:254-259.
16. Turna A., Pekcolaklar A., Urer N., Sayar A., Gurses A. Prognostic significance of p53 and epidermal growth factor receptor expression in resected surgical-pathologic t1 non-small cell lung cancer: analysis in combination with histopathological factors. Adv Mol Med 2006, 2:119-125.
17. Bos M., Mendelsohn J., Bowden C., Pfister D., Cooper M.R., Cohen R., et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc Am Soc Clin Oncol 1996, 15:1381.
18. Selvaggi G., Novello S., Torri V., Leonardo E., De Giuli P., Borasio P., et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004, 15:28-32.
19. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7:603-607.
20. Onn A., Correa A.M., Gilcrease M., Isobe T., Massarelli E., Bucana C.D., et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004, 10:136-143.
21. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
22. Ahn J.H., Kim S.W., Hong S.M., Suh C., Kim W.K., Lee I.C., et al. Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 2004, 19:529-535.
23. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3:515-522.
24. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996, 2:1411-1416.
25. Tanaka F., Yanagihara K., Otake Y., Kawano Y., Miyahara R., Takenaka K., et al. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol 2004, 11:612-618.
26. Yoo J., Jung J.H., Lee M.A., Seo K.J., Shim B.Y., Kim S.H., et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22:318-325.
27. Suzuki M., Iizasa T., Ko E., Baba M., Saitoh Y., Shibuya K., et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002, 35:29-34.
28. Sulzer M.A., Leers M.P., van Noord J.A., Bollen E.C., Theunissen P.H. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 1998, 157:1319-1323.
29. Retera J.M., Leers M.P., Sulzer M.A., Theunissen P.H. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol 1998, 51:891-894.
30. Pantel K., Passlick B., Vogt J., Stosiek P., Angstwurm M., Seen-Hibler R., et al. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol 1998, 16:1407-1413.